Clever Culture Secures $2.6M to Develop APAS Revolution
The funding package supports development of a smaller-format automated culture system for lower-volume manufacturing facilities.
Updated on Nov. 3, 2026 in Biotech
Clever Culture Systems has secured a $2.6 million funding package, comprising a $1 million share placement and a $1.6 million unsecured loan, to develop its APAS Revolution system. The company also appointed PSC Biotech as sales agent for APAS Independence in North America, Canada and Singapore.
Why it matters
The funding moves APAS Revolution toward commercial availability, targeting a product aimed at customers seeking a smaller system for lower-volume manufacturing. The funds also retire an existing $1.7 million short-term loan due December 31, 2026.
The $1.6 million loan carries a 10% annual interest rate and issues 19.2 million unlisted options, with the placement including one option per new share exercisable at 3 cents by November 30, 2029. Development leverages the imaging station, plate-gripping system and AI-powered analysis modules of APAS Independence, while the final product launch is targeted for H1 CY28.
The players
Clever Culture Systems
An automated microbiology company whose APAS platform is used by some of the largest pharmaceutical companies globally.
PSC Biotech
A sales agency appointed to represent APAS Independence in North America, Canada and Singapore.
The details
Development of APAS Revolution responds to customer demand for a smaller-format system suited to lower-volume facilities and draws on the existing APAS Independence platform. Pre-production instruments are expected to be available for customer evaluation during CY27.
Timeline
October 29: Last traded price used as the placement discount reference.
December 31, 2026: Existing $1.7 million short-term loan due for repayment.
November 30, 2027: Principal of the $1.6 million loan repayable.
CY27: Pre-production APAS Revolution instruments available for customer evaluation.
H1 CY28: Targeted final product launch.
The Tech Race
APAS Revolution extends the APAS Independence platform into a smaller format, with the company projecting that the new system could lift the estimated total addressable market for APAS from $2.8 billion to $4.3 billion. The move positions Clever Culture against rivals in automated microbiology by widening the range of facility sizes it can serve.
For laboratories and manufacturers, a smaller automated culture system could offer a lower-volume option once APAS Revolution reaches the market. Customers evaluating the system will have access to pre-production instruments before the planned launch.
The takeaway
Smaller-format automation may widen access to advanced culture systems for facilities that lack the volume to justify larger platforms. Readers tracking the sector should watch the CY27 evaluation phase for evidence of customer uptake.
What happens next
Pre-production APAS Revolution instruments are expected for customer evaluation in CY27, with the final product launch targeted for H1 CY28.
Further reading
Explore more stories in Biotech for context on automated laboratory platforms.
Source note: This article includes information reported by Stockhead.
